ArticleTransfusion2026
Residual risk of human immunodeficiency virus, hepatitis C, and hepatitis B following implementation of sexual risk behavior-based screening in Canada.
Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2022, Canadian Blood Services implemented a gender-neutral sexual behavior-based screening (SBBS) approach to donor deferral, replacing time-based criteria targeting gay, bisexual and other men who have sex with men (gbMSM) and female partners of gbMSM. We assessed the impact of this policy change on human immunodeficiency virus (HIV), hepatitis C (HCV), and hepatitis B (HBV) prevalence, incidence, and residual risk. STUDY DESIGN AND
methodsWe compared prevalence rates among first-time donors, incidence rates, and residual risk for allogeneic donations made in the 3 years pre-SBBS implementation and 3 years post-SBBS implementation.
resultsHIV and HBV prevalence remained steady while HCV prevalence increased among first-time donors post SBSS-implementation. Point estimates for incidence rates and residual risks decreased for each marker post-implementation, but differences were not significant. Residual risks post-implementation were 1 in 34.7 million for HIV, 1 in 64.1 million for HCV, and 1 in 3.1 million for HBV. DISCUSSION: Residual risks of infection remain low following the implementation of a gender-neutral sexual risk behavior-based approach to donor deferral. This policy change has not negatively impacted the safety of the Canadian blood supply.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.